# Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease

> **NCT04429867** · PHASE4 · UNKNOWN · sponsor: **WellStar Health System** · enrollment: 700 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04429867
- **Lead sponsor:** WellStar Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-07
- **Primary completion:** 2020-12-07
- **Final completion:** 2020-12-07
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04429867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04429867, "Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04429867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*